News Release: Emory Healthcare , Research , School of Medicine

Sep. 24,  2010

Promising Results in Groundbreaking Heart Valve Study At Emory

News Article ImageEmory heart patient, Glenrose Gay of Vidalia was the first person in GA to receive a new aortic valve via catheter. Pictured here in 2007 with Emory cardiologists, Drs. Peter Block (left) and Vasilis Babaliaros.

A new way of replacing diseased aortic heart valves in patients too frail or sick to withstand the traditional open-heart surgical approach proves promising in a study published this week in the New England Journal of Medicine (NEJM). 

Since October 2007, Emory University Hospital has been one of approximately 20 hospitals nationwide, and the only site in Georgia, studying the groundbreaking non-surgical treatment option for patients suffering from severe aortic stenosis. The life threatening heart condition affects tens of thousands of Americans each year when the aortic valve tightens or narrows, preventing blood from flowing through normally.

As part of the Phase II clinical trial, Emory Heart & Vascular Center cardiologists and cardiothoracic surgeons performed transcatheter aortic valve implantation (TAVI) comparing this procedure with traditional, open-heart surgery or medication therapy in high-risk patients with aortic stenosis.

The study followed 358 patients who received either catheter-delivered valves or standard non-surgical treatment. The findings showed that patients who had replacement heart valves delivered by catheter were more likely to survive a year than patients who were treated without replacing their original valves. According to the authors, catheter-delivered valves “should be the new standard of care” for patients who are not able to undergo surgery.

During the innovative TAVI procedure, doctors create a small incision in the groin or chest wall and then feed the new valve, mounted on a wire mesh on a catheter. Once the catheter is properly positioned in the opening of the aortic valve, the new valve is rapidly expanded. As it expands it pushes the diseased, native valve aside, allowing blood to flow normally through the implanted valve to the rest of the body.

 “These results show great promise for patients with severe aortic stenosis and help us make a giant step forward in our battle against this common disease,” says Peter Block, MD, professor of medicine, Emory School of Medicine and principal investigator of the study at Emory. “They are especially important since the number of people with failing valves is expected to greatly increase as baby boomers continue to age.”

Aortic valve stenosis often occurs with age, most commonly among elderly patients over 70 years of age, but can surface earlier in life in those with rheumatic heart disease or congenital abnormalities of the valve. Patients often develop symptoms of chest pain, shortness of breath, fainting spells and heart failure.

Block and fellow interventional cardiologist Vasilis Babaliaros, MD, assistant professor of medicine at Emory University School of Medicine, led the Emory clinical trial along with their cardiac surgical colleagues Robert Guyton, MD, professor of surgery and chief, Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine, and Vinod Thourani, MD, associate professor of surgery, Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine.

Babaliaros spent several years abroad with French cardiologist Alain Cribier, MD, who successfully implanted the first catheter-delivered valve in 2002 in a seriously ill patient with aortic stenosis who had been refused for surgery. Babaliaros worked alongside Cribier to learn the new approach and bring it to the United States and to Emory.

Transcatheter aortic valve implantation is not yet approved by the U.S. Food and Drug Administration (FDA) and therefore is only available in a few centers throughout the country, including Emory, the first center in the Southeast and one of the five largest centers in the country. Approximately 90 patients have received new valves at Emory since the clinical trial started in 2007.  It is anticipated that this valve will receive FDA approval in late 2011.

Emory Heart & Vascular Center doctors are committed to providing clinically excellent cardiovascular patient care, pioneering innovative clinical research and training the best heart specialists in the world. The Center is consistently recognized by U.S. News & World Report as one of the top heart centers in the country.

For more information on the TAVI procedure at Emory, please contact the Andreas Gruentzig Cardiovascular Center of Emory University at 404-712-7667.

###

The Robert W. Woodruff Health Sciences Center of Emory University is an academic health science and service center focused on missions of teaching, research, health care and public service.

Learn more about Emory’s health sciences:
Blog: http://emoryhealthblog.com
Twitter: @emoryhealthsci
Web: http://emoryhealthsciences.org

News Release Tools

  • Print

News Releases

The news release you are currently viewing is part of an archive of Emory health sciences press releases, dating Sept. 2008 - Dec. 2011.



To View Current Releases


Emory News Center

Emory News Center



To View News Archives


News Archives

News Archives